Table 2.

Summary of potential melanoma-derived EV protein markers as described in this review.

Protein Marker	Melanoma Cell Line	In Vivo	Function
HSP70	SK-Mel-2 [32], -5 [32], -28 [25,32,52], -202 [25], -265 [25], -35 [25]; B16-F10 [25]; LOX IMVI [32]; M14 [32]; Malme-3M [32]; MeWo [52]; MDA-MB-435 [32]; UACC-62 [32], -257 [32]	Human plasma [25]	Detection [25]
Caveolin-1	LOX IMVI [32]; M14 [32]; Malme-3M [32]; Me501 [53]; MDA-MB-435 [32]; SK-Mel-2 [32], -5 [32], -28 [32]; UACC-62 [32], -257 [32]	Human plasma [53]	Detection [53]
Mel-CAM	SK-Mel-28 [52]; MeWo [52]		Detection [25]
Mart-1	SK-Mel-28 [52]; MeWo [52]; RMS [54]		Detection [25]
TRP-1	RMS [54]		Detection [25]
TRP-2	B16-F10 [25]; SK-Mel-28 [25], -202 [25], -265 [25], -35 [25]; RMS [54]	Human plasma [25]	Detection [25], monitor progression [25]
PMEL	LOX IMVI [32]; M14 [32]; Malme-3M [32]; MDA-MB-435 [32]; SK-Mel-2 [32], -5 [32], -28 [32]; UACC-62 [32], -257 [32]	Malignant effusions [49]	Detection [49]
VLA-4	B16-F10 [25]; SK-Mel-28 [25], -202 [25], -265 [25], -35 [25]	Human plasma [25]	Detection [25]
CSPG4	LOX IMVI [32]; M14 [32]; Malme-3M [32]; MDA-MB-435 [32]; SK-Mel-2 [32], -5 [32], -28 [32]; UACC-62 [32], -257 [32]	Plasma [50,55]	Detection [50,55]
MET	B16-F10 [25]	Human plasma [25]	Detection [25], monitor progression [25]
MIA	Malme-3M [32]; SK-Mel-2 [32], -5 [32], -28 [32]; UACC-62 [32], -257 [32]	Human plasma [77]	Monitoring progression [77]
S100B	LOX IMVI [32]; Malme-3M [32]; MDA-MB-435 [32]; SK-Mel-2 [32], -5 [32], -28 [32]; UACC-257 [32]	Human plasma [77]	Monitoring progression [77]
PD-L1	SK-Mel-2 [51]; B16-F10 [51]	Human plasma [51,78]	Detection [78], monitoring progression [51]